



Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1

Joseph J. Jablonski^a, Dipwanita Basu^c, Daniel A. Engel^{b,c,*}, H. Mario Geysen^a

^a University of Virginia, Department of Chemistry, Charlottesville, VA 22904, USA

^b Department of Microbiology, University of Virginia School of Medicine, 1300 Jefferson Park Ave., Jordan Hall 7224, Charlottesville, VA 22908, USA

^c Alexander BioDiscoveries, LLC, Charlottesville, VA 22908, USA

ARTICLE INFO

Article history:

Received 16 July 2011

Revised 3 October 2011

Accepted 10 October 2011

Available online 19 October 2011

Keywords:

Influenza virus

Antiviral

Medicinal chemistry

Non-structural protein 1 (NS1)

Drug

ABSTRACT

Influenza is a continuing world-wide public health problem that causes significant morbidity and mortality during seasonal epidemics and sporadic pandemics. The existing vaccination program is variably effective from year to year, and drug resistance to available antivirals is a growing problem, making the development of additional antivirals an important challenge. Influenza virus non-structural protein 1 (NS1) is the centerpiece of the viral response to the host interferon (IFN) system. NS1 was demonstrated previously to be a potential therapeutic target for antiviral therapy by the identification of specific small-molecule inhibitors. One inhibitory compound, NSC125044, was subjected to chemical evaluation. Initial synthetic work comprised simplifying the core structure by removing unwanted functionality and determination of key features important for activity. Several subclasses of molecules were designed and synthesized to further probe activity and develop the basis for a structure–activity relationship. Apparent potency, as judged by activity in virus replication assays, increased dramatically for some analogs, without cytotoxicity. Results suggest that the target binding site tolerates hydrophobic bulk as well as having a preference for weakly basic substituents.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Influenza is a continuing worldwide public health problem. The World Health Organization estimate of annual mortality due to seasonal influenza is 250,000–500,000, and there are approximately 30,000 influenza associated deaths and 200,000 hospitalizations in the United States per year.¹ Severe infections are most commonly seen in the elderly, the very young, and the chronically ill.^{2–4}

In addition to seasonal epidemics, there have been four documented influenza pandemics during this and the previous century, the most serious occurring in 1918. During an eight month period the 1918 Spanish influenza claimed 20–40 million lives.⁵ Two subsequent pandemics in 1957 and 1968 were less severe but shared the characteristic of having avian origin.⁶ There is concern that another devastating pandemic is inevitable, perpetuated by the spread of the avian H5N1 virus through multiple bird populations in Asia, Africa and Europe, which periodically causes human infections.^{7–10} Although avian H5N1 has not acquired the ability to transmit from person to person, those who are infected through direct contact with birds are at a very high risk for mortality, approximately 60%.^{11,12} The H1N1 swine influenza pandemic of 2009 has added weight to concerns regarding the pandemic threat.^{13–15}

The most common method for combating influenza virus is vaccination. However, viral antigenic drift dictates that a new vaccine be developed each year, and the effectiveness of the vaccine is variable.¹⁶ In addition there are obstacles to worldwide vaccine distribution, and reluctance on the part of some to vaccine administration.¹⁷ Two classes of drugs have been used to treat influenza infections, including one that targets the viral M2 ion channel and one that inhibits the viral neuraminidase protein. Due to the emergence of viral strains that are resistant to M2 and neuraminidase inhibitors, the variable effectiveness of seasonal vaccines, and the high probability of future pandemics, it is important to identify additional viable viral targets to treat the influenza infections.¹⁸

Previously we identified non-structural protein 1 (NS1) of influenza virus as a novel drugable antiviral target.^{1,19} NS1 is encoded by all strains of influenza A and is highly conserved.^{20–22} It is a multifunctional protein with essential roles in viral replication and evasion of the cellular innate immune response. The central role of NS1 in virus propagation and spread make it an attractive drug target.^{20,21} Numerous studies have shown that NS1 participates in a wide range of functions. NS1 binds to double stranded RNA in a non-sequence specific manner.^{23,24} In doing so NS1 is able to shield dsRNA from detection by the 2'–5' oligo(A) synthetase (OAS)/RNase L pathway, which is responsible for degradation of viral RNA.²⁵ NS1 also binds to the 30 kDa subunit of cleavage and polyadenylation specificity factor (CPSF30), and poly (A)-binding protein II.^{26,27} In

* Corresponding author. Tel.: +1 434 924 8633; fax: +1 323 982 1071.

E-mail address: dae2s@virginia.edu (D.A. Engel).

doing this the 3'-end processing of cellular mRNAs is inhibited, impeding the metabolism of essential RNAs. Among these are mRNAs for interferons (IFNs), which are produced in response to viral infection.^{26–29} Additionally NS1 associates with cellular protein kinase R (PKR), thereby preventing it from phosphorylating translation elongation factor eIF-2 α and allowing viral protein synthesis to continue.^{30,31} Recently, it has been demonstrated that NS1 interacts with TRIM25. This interaction prevents the activation of retinoic acid-inducible gene I (RIG-I), thereby suppressing the production of cellular IFN.^{32–34}

In a recent study we identified several compounds that specifically inhibit NS1 function in cells.¹ Importantly, four of the compounds with anti-NS1 activity also demonstrated significant antiviral activity in cell culture assays and reversed NS1-dependent blockade of the cellular interferon synthesis pathway.¹ In this report we describe the design, synthesis and biological testing of a series of compounds based on one of the compounds reported previously, NSC125044. These studies have resulted in several highly potent antiviral compounds.

2. Results

2.1. Method validation

Efficacy of an antiviral compound in cell culture is a complex function of its activity, permeability, and other factors. In addition, virus replication is a multi-dimensional non-linear process, so the overall effect of chemical inhibition of a viral target may be complex as well. In the case of inhibition of NS1 function there is the added complexity of the interplay between NS1 and the host cell innate immune response, which involves modulation of cellular interferon production and the consequences of its downstream antiviral effects.²⁰

As described in Methods a live cell virus replication assay was used throughout this study. Interestingly, in comparing the efficacy of compounds we noticed that we could discriminate between them based two parameters, (1) apparent potency and (2) maximum efficacy. Medicinal chemistry decisions took both factors into account. To fully present our data we have included graphs depicting representative concentration curves for some compounds so that these can be inspected visually (in Figures or [Supplementary data](#)). Furthermore, examination of the general shape of the relationship between $\text{Log}_{10}(\text{virus titer})$ and concentration suggested an exponential decay that approached a residual virus replication level at high compound concentrations. This analysis yielded two parameters of interest: (1) a constant K , indicative of apparent potency and (2) a maximum inhibition of virus replication (maximum efficacy), being the difference between the no-compound value and that observed at high concentrations. To establish that this relationship held for compounds of low and high activity three analogs were chosen and assayed in triplicate. As can be seen from [Figure 1](#), in each case the data were an excellent fit to an exponential decay relationship with readily determined values of K and maximum efficacy. For some of our early compound series, data were collected to determine the maximum inhibition of virus replication at a single, high concentration (e.g., [Table 1](#)), which provided sufficient information to make initial medicinal chemistry decisions.

Table 1

Compound	LogTCID_{50}^a (viral titer)	Fold decrease in replication ^b
Control (DMSO)	8.5	—
A1	7.1	25
A8	7.1	25
A9	5.7	630
A11	6.8	50
A12	6.2	200
A13	6.5	100
A14	6.3	158
A15	5.8	500
A16	6.5	100

^a Viral titer, expressed as logTCID_{50} , was determined from supernatants of MDCK cells infected for 48 h and treated for the entire period with 50 μM of the indicated compounds.

^b Fold decrease in virus replication was determined by subtracting the logTCID_{50} value for each compound from 8.5 (control value, see [Table](#)) and calculating the inverse log.




Figure 1. Determination of decay constant K constant for virus replication in cells treated with NS1 inhibitors. Cells were infected with influenza virus A/PR/8/34, treated with the indicated compounds and analyzed for virus production as described in Methods. Determination of K was based on a fit to a first order exponential relationship.

2.2. Replacement of compound A1 indane with simple benzene ring retains activity

As previously reported compound A1 (NIH compound NSC125044) was identified from a screen for functional inhibitors of NS1.¹ Examination of A1 in terms of developing a structure–activity relationship (SAR) suggested that the right hand side





Figure 2. Hydrazide analogs.

(RHS) indane was the least amenable to chemical manipulation, and commercial availability of building blocks was judged an impediment. In a first series of compounds (Fig. 2; A2–A7) we therefore examined the necessity of the indane ring to the inhibition of virus replication. Analogs introducing a variety of alternative functionalities to the indane were synthesized through the use of *para*-substituted benzaldehyde derivatives (Scheme 1). These compounds were assessed using a single high concentration (50 μ M) to compare their maximum efficacies. None of the resulting compounds (A2–A7) were significantly different in activity from compound A1 (data not shown). Modifications included incorporation into the benzene ring of either electron donating or withdrawing substituents, as with hydrogen bond donating and accepting functional groups. Additionally, replacement of the indane with naphthalene (A3) was accomplished. Of the analogs synthesized, compound A2 contained a simple benzene ring to replace the indane. Given the difficulty of pursuing an SAR with retention of the indane ring system it was decided to use analog A2 as the basis for further development.

2.3. Removal of hydrazine, and carbon spacer optimization

The hydrazine functionality of compounds A1 and A2 is an unattractive feature with potentially poor pharmacokinetic properties. Three molecules were synthesized that retained the amide bond nitrogen, but replaced the other with an alkyl chain (Fig. 3). A8 was synthesized using 2-phenylethylamine as one of the building blocks with retention of the bond distance between the two rings. This substitution exhibited similar inhibitory activity to the compound A1 hydrazine parent (Table 1), and indicated that the hydrazine is not an essential motif required for activity. Further studies explored the chain length between the amine and the phenyl ring. Compound A9 with a three carbon spacer resulted in a substantial increase in activity over a wide concentration range (Table 1, Figs. 1 and 3). Also the maximum effects of A1 and A9 at high concentrations were substantially different as illustrated in Figure 3. Compounds A1 and A9 were found to be non-toxic to MDCK cells up to up to 100 μ M concentration.^{1,19} It was observed that the three and four carbon chain spacers (A9 and A10) displayed approximately the same activity (not shown). With the better commercial availability of building block sets, the three carbon analog (A9) was chosen over the four carbon A10 as the new lead



*Yields were not obtained based on experimental protocol

A2[R₁] = Phenyl
A3[R₁] = Naphthyl
A4[R₁] = p-Chlorophenyl
A5[R₁] = p-Hydroxyphenyl
A6[R₁] = p-Methoxyphenyl
A7[R₁] = p-Nitrophenyl

Scheme 1.





Figure 3. *Ortho* hydroxybenzamide analogs.

molecule. These positive results confirmed the previous findings regarding substitution of the phenyl ring on the right hand side, and also simplified the synthetic protocols from four steps down to one (see Scheme 2).



Scheme 2.

2.4. Position of the left hand side hydroxyl

In A9, the phenol hydroxyl is *ortho* with respect to the amide linking group. As shown in Table 1 and Figure 4, analogs with




Figure 4. Benzamide analogs.

either the hydroxy in the *meta* or *para* position (A12 and A13), resulted in decreased activity. Furthermore, the incorporation of a simple benzene ring (A11) also led to a decrease in activity. These results indicated a preference for an *ortho* substituted phenyl ring as the preferred left hand side (LHS) functionality.

2.5. Substitution at the left hand side *ortho* position

The optimum substitution pattern for the molecule was determined to be the *ortho* position. To examine the requirement for a hydroxyl group, as in A9, various *ortho* substituted benzoic acids were selected to produce analogs A14–A22 (Fig. 5) and to further explore electronic effects at this position on virus inhibition.

No clear trend was observed. Methyl (A14) and methoxy (A15), both weaker electron donating groups than hydroxyl led to weaker virus inhibition (Table 1). Compounds A16 (Table 1) and A21 (Fig. 5) also showed weak activity. In contrast a substantial increase in virus inhibition was observed for the *ortho* substituted amino (A22 *K* = 1.40 compared to A9 *K* = .126; see also Fig. 5). Like compound A9, compound A22 was found to be non-toxic in MDCK cells up to 100 μM (data not shown). Some halogen analogs (A18 and 20) but not others (A17 and A19) also displayed greater





Figure 5. Phenylpropylamide analogs.

activity than compound A9; see [Supplementary Figure S1](#). These results would seem to rule out hydrogen bonding, either as an acceptor or donor, as a role for the hydroxy functionality in interacting with its target. An additional consideration is the possible intramolecular hydrogen bonding between the *ortho* hydroxyl group and the carbonyl group through a six-membered ring. This can partially lock the molecule in a conformation which may affect compound cell permeability. Also of interest was the finding that analog A20 (1-substituted) at high concentrations gave a lower overall reduction in virus replication than the parent hydroxy containing analog despite a greater apparent potency at lower concentrations (see [Supplementary Fig. S1](#)).

2.6. Increased hydrophobic bulk on the left hand side increases activity

While retaining a hydroxy functionality *ortho* to the linking amide bond, possible size restrictions associated with the LHS of the molecule were examined. Three, hydroxy-naphthoic acid derivatives were used in the synthesis of new compounds ([Fig. 6](#)). Each of these analogs (A23–A25) project the second aromatic ring in a different direction probing both the size and shape of the target binding site. The observed virus inhibition of these analogs was similar (A23 $K = .657$; A24 $K = .546$; A25 $K = .658$; see also [Supplementary Fig. S2](#)) but significantly better than for the parent (A9, $K = 0.126$), suggesting a large hydrophobic LHS binding pocket in the binding site. The activity of analog A26 ($K = 0.15$), another non-aromatic fused ring system but without the presence of the *ortho* hydroxy function, is consistent with this hypothesis but has overall weaker activity due to its unsubstituted benzene LHS, as also observed for A11 ([Table 1](#)).




Figure 6. Naphthoic acid analogs.

2.7. Pyridyl and quinolyl analogs

As mentioned above it was demonstrated that replacing the α -hydroxy group by an amine led to greater virus inhibition for compound A22 ($K = 1.40$). Using picolinic acid ([Fig. 7](#)) for the LHS (A27), with a weakly basic ring nitrogen, was less active ($K = 0.771$). Combination of the ring nitrogen in the context of the naphthalene ring system, analogs A28–A30, were synthesized to take advantage of the suggested larger LHS binding site ([Fig. 7](#)). These three quinolyl derivatives, similar to the naphthalene fused ring systems series




Figure 7. Pyridyl analog A27 and quinolyl analogs A28–A30.

(A23–A25), showed an improvement in virus inhibition activity over compound A27, with compound A28 being somewhat more active ([Supplementary Fig. S3](#)).

2.8. Examination of multiple aromatic substitutions on the left hand side

Having determined that both hydroxy and amine *ortho* substituted benzamides, and the dual ring system analogs, showed potent virus inhibition activity, a series of analogs with more than one functionality in the LHS were synthesized ([Fig. 8](#); compounds A31–A34). For compound A31, addition of an amino group *para* to the amide group increased activity a small amount compared with A9 (A9 $K = 0.126$; A31 $K = 0.22$). Similarly the addition of a *para*-substituent, chloro (A33, $K = 0.27$), methoxy (A32, $K = 0.73$) or nitro (A34, $K = 0.86$) gave analogs with increased virus inhibitory activity ([Supplementary Fig. S4](#)).




Figure 8. Disubstituted benzamide analogs.




Figure 9. Examination of the linking region.

2.9. Examination of the linking region

In a last set of analogs (Fig. 9) we explored within the linking chain between the LHS and RHS, the requirement of a secondary amide (A35), the position of the amide bond (A36–A38), and the direction of the amide bond (A39). In all cases these analogs were less active than the corresponding *ortho* hydroxy parent A9 (data not shown). Of more interest were analogs A40 and A41, two compounds in which the RHS-most methylene was replaced by an ether oxygen. This mode of assembly was chosen to allow future development of the RHS SAR, via incorporation of substituted phenols, of which many versions are commercially available. In the case of the *ortho*-amino analog virus inhibitory activity was unchanged, (A22, $K = 1.40$ to A41, $K = 1.46$), whereas for the *ortho*-hydroxy analog a substantial increase was observed, (A9, $K = 0.126$ to A40, $K = 1.15$). Data for compounds A40 and A41 can be found in Supplementary Figure S5.

3. Discussion

Starting from hit NSC125044 (compound A1), obtained from a screen as reported previously,¹ a systematic analoging approach has yielded a simple molecule that inhibits virus replication in cells by greater than three orders of magnitude (Figs. 5, 10 and Supplementary Fig. S5). This is virtually the same magnitude of effect on replication observed with a virus carrying a deletion of the NS1 gene ('delNS1') in the A/PR/8/34 background, the same used in this study.³⁵ This strongly suggests that members of the compound series reported here are capable of nearly complete abolishment of NS1 function in the cellular context. Interestingly, 100% of mice




Figure 10. Improvement in apparent potency and maximum efficacy in cell culture.

inoculated with the delNS1 virus survived infection, indicating that ablation of NS1 function is strongly protective in vivo.³⁵ In vivo studies with several of the compounds reported here are ongoing.

Not surprising is the finding that the many of the features of the originally identified molecule NSC125044 were not essential for activity; with only ~ 2000 compounds library used in the initial screen the likelihood of obtaining a near optimal molecule is very small. As was shown in these studies, optimally the LHS requires a large hydrophobic core with a weakly basic function, the RHS was adequately represented as a simple aromatic ring, and the linking region comprised a left justified amide bond followed by a 3 or 4 methylene chain.

The SAR as developed herein relied on a resource intensive cell culture virus replication assay. In this context it is recognized that the SAR is at a minimum the combination of both the cell penetration properties of the molecule as well as its ability to bind its molecular target. As shown in Figure 5, compound A22 triggered a greater than $2 \log$ effect on replication at $1 \mu\text{M}$, indicating that the K_D for its target is quite low. Nonetheless, establishment of a direct binding assay will allow direct comparison of analogs in terms of binding constants (K_D values), and further chemical optimization based on affinity. Experiments of this type are being pursued.

4. Experimental

4.1. Biological methods

4.1.1. Mammalian cells and viruses

MDCK cells were maintained in Iscove medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine. Medium and serum were from Invitrogen. For infections, viral stocks were diluted in growth medium supplemented with 0.3% bovine serum albumin, 0.22% sodium bicarbonate, and 0.25 U of TPCK (toylsulfonyl phenylalanyl chloromethyl ketone)-trypsin (Invitrogen)/mL. Influenza virus A/PR/8/34 was propagated in 10-day-old embryonated chicken eggs at 37°C . Titers of influenza virus were determined by 50% tissue culture infective dose (TCID_{50}) analysis on MDCK cells using the hemagglutination assay protocol of Reed and Muench.³⁶

4.1.2. Virus replication assays

Confluent cell monolayers were infected at a multiplicity of infection (MOI) of 0.1 for 48 h in the presence or absence of compound or DMSO. Compounds were added at the beginning of infection and were present throughout the infection. After 48 h virus titers were determined by TCID_{50} analysis as described previously.³⁶

4.2. Chemistry

Reagents and solvents used for synthesis were reagent grade and used as received. HOBt and DIC were purchased from Advanced ChemTech/Creosalus. HPLC grade H₂O and MeCN were purchased from VWR and were used as received. All other reagents and solvents were purchased from Acros Organics, Fisher Scientific, or Sigma–Aldrich. ¹H NMR spectra were obtained using a Varian UnityInova 300/54 at 300 K unless otherwise noted. Chemical shifts were reported in parts per million (δ) relative to the solvent as follows: CDCl₃ (δ 7.24) and DMSO-*d*₆ (δ 2.50). NMR spectra data are abbreviated as follows: s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet.

High-resolution mass spectrometry data was obtained from the Mass Spectrometry Laboratory in the School of Chemical Sciences at the University of Illinois Urbana-Champaign (Urbana, IL). All analytical High Performance Liquid Chromatography analysis was performed using Gilson Unipoint software and analytical equipment. This includes Gilson 215 Liquid Handler, Gilson 306 pumps, Gilson 811c Dynamic Mixer, Gilson 806 Manometric Module, and a Gilson 170 Diode Array Detector with deuterium lamp. The column used was a Thomson Instrument Inc. Advantage C18, 60A, 5u, 250 × 4.6 mm column. In conjunction with the HPLC analysis, mass spectrometry data was collected simultaneously using a single quad PE SCIEX API 150EX mass spectrometer utilizing Analyst software. A two-solvent mobile phase gradient was used for all LCMS analysis, starting at 90% water/0.01% TFA and 10% acetonitrile/0.01% TFA. The mobile phase changed linearly to 100% acetonitrile/0.01% TFA over 10 min. The 100% acetonitrile/0.01% TFA phase was held for an additional 10 min. A constant flow rate of 1.0 mL/min was maintained for the duration of analysis. Retention times are reported in minutes and abbreviated as *t*_R; mass to charge ratios are reported as *m/z*.

Preparative HPLC was performed using a Gilson 215 Liquid Handler, Gilson 306 pumps, Gilson 811c Dynamic Mixer, Gilson 805 Manometric Module, and a Gilson UV/VIS-156 detector. A Thomson Instrument Inc. Advantage C18, 60A, 5u, 250 × 10.0 mm column and a Thomson Instrument Inc. Advantage C18, 60A, 5u, 250 × 21.2 mm column were used in the purification of samples. A two-solvent mobile phase gradient was used which started at 90% water/0.01% TFA, 10% acetonitrile/0.01% TFA and changed linearly to 100% acetonitrile/0.01% TFA over 10 min. The 100% acetonitrile/0.01% TFA phase was held for an additional 10 min. When the 250 × 10.0 mm column was used, a constant flow rate of 5.0 mL/min was used. When the 250 × 21.2 mm column was used, a constant flow rate of 18.0 mL/min was used for the duration of the method.

4.2.1. General procedure A for the final imine synthesis

The benzhydrazide was dissolved in a 1:1 mixture of triethyl orthoformate in DCM. To this, 1.1 equiv of the benzaldehyde derivative were added and the reactions were mixed overnight at room temperature. LCMS analysis of the reaction mixture indicated the formation of the desired product. The reaction mixture was concentrated under reduced pressure and preceded directly to preparative HPLC purification without further work-up.

4.2.2. General procedure B—amide bond formations which lead to final products

One milli mole of the carboxylic acid was dissolved in DCM. To this, 1.1 equiv of HOBt and the desired primary amine were added. Following this, 1 equiv of DIC was added to the mixture and the reaction was mixed overnight. Upon completion of the reaction, the diisopropylurea was filtered away and the DCM layer was washed with saturated bicarbonate solution (1×) and 2 M HCl (1×). The organic layer was dried over anhydrous sodium sulfate

and the solvent was then removed under reduced pressure. Typical yields for all amide bond formations were ≥80%. A small portion of the resulting compounds were carried through and used for HPLC purification.

4.2.3. *tert*-Butyl hydrazinecarboxylate

To a round bottom flask equipped with a stir bar, 25 mmol of hydrazine monohydrate was dissolved in THF at 0 °C. Added drop-wise to this was a solution of Boc₂O in THF. The reaction was allowed to mix at 0 °C for an additional hour. The reaction was then diluted with ethyl acetate and washed with water (2×). The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure. 3.53 mmol of desired product was collected (70% yield). LCMS: *t*_R = 7.23 min. *m/z* = 133.2 (M+H).

4.2.4. *tert*-Butyl 2-(2-hydroxybenzoyl)hydrazinecarboxylate

The 3.53 mmol of *tert*-butyl hydrazinecarboxylate was dissolved in DCM in a round bottom flask with a stir bar. To this, 1.1 equiv of HOBt and salicylic acid were added at room temperature. Following this, 1 equiv of DIC was added to the flask. The reaction was mixed overnight at room temperature. Upon completion of the reaction, the DIU was filtered away and the resulting DCM was washed with saturated bicarbonate solution (1×) and 2 M HCl (1×). The organic layer was dried over Na₂SO₄ and pumped down under reduced pressure to produce a white solid. This produced 3.34 mmol of the desired product (94% yield). LCMS: *t*_R = 9.68 min. *m/z* = 253.2 (M+H).

4.2.5. 2-Hydroxybenzohydrazide

The 3.34 mmol of *tert*-butyl hydrazinecarboxylate which was collected was dissolved in a 1:1 mixture of TFA in DCM in a round bottom flask equipped with a stir bar. The reaction was mixed for 1 h and then the excess TFA and DCM was removed under vacuum for 1 h producing a clear oil (quant). The crude reaction material was carried on to the next step without further purification steps.

4.2.6. *N'*-Benzylidene-2-hydroxybenzohydrazide TFA salt (A2)

General procedure A was used to form the imine bond using benzaldehyde to produce a white solid. ¹H NMR (300 MHz, DMSO) δ 11.96–11.85 (m, 2H), 8.45 (s, 1H), 7.87 (d, *J* = 6.4 Hz, 1H), 7.76–7.70 (m, 2H), 7.49–7.37 (m, 4H), 7.00–6.87 (m, 2H), 6.54 (s, 1H). LCMS: *t*_R = 10.45 min. *m/z* = 241.3 (M+H).

4.2.7. 2-Hydroxy-*N'*-(naphthalen-2-ylmethylene)benzohydrazide TFA salt (A3)

General procedure A was used to form the imine bond using 2-naphthaldehyde to produce an off-white solid. ¹H NMR (300 MHz, DMSO) δ 10.17 (s, 1H), 9.34 (s, 1H), 8.59 (s, 1H), 8.21–7.83 (m, 5H), 7.62–7.50 (m, 2H), 7.47–7.38 (m, 1H), 7.08–6.88 (m, 3H), 6.54 (s, 1H). LCMS: *t*_R = 11.68 min. *m/z* = 291.0 (M+H).

4.2.8. *N'*-(4-Chlorobenzylidene)-2-hydroxybenzohydrazide TFA salt (A4)

General procedure A was used to form the imine bond using 4-chlorobenzaldehyde and produced an off-white solid. ¹H NMR (300 MHz, DMSO) δ 12.00–11.69 (m, 1H), 10.18 (s, 1H), 9.51–9.24 (m, 1H), 8.16–8.07 (m, 1H), 8.07–7.99 (m, 1H), 7.85–7.70 (m, 1H), 7.64–7.53 (m, 3H), 7.48–7.34 (m, 1H), 7.10–6.99 (m, 1H), 6.54 (s, 1H). LCMS: *t*_R = 11.45 min. *m/z* = 274.9 (M+H).

4.2.9. 2-Hydroxy-*N'*-(4-hydroxybenzylidene)benzohydrazide TFA salt (A5)

General procedure A was used to form the imine bond using 4-hydroxybenzaldehyde. An off-white solid was produced after HPLC purification. ¹H NMR (300 MHz, DMSO) δ 11.98 (s, 1H), 11.68 (s, 1H), 9.97 (s, 1H), 8.33 (s, 1H), 7.87 (d, *J* = 8.2 Hz, 1H), 7.56 (d,

$J = 8.4$ Hz, 2H), 7.48–7.35 (m, 1H), 6.94 (d, $J = 7.7$ Hz, 2H), 6.90 (s, 1H), 6.83 (d, $J = 8.5$ Hz, 2H). LCMS: $t_R = 8.90$ min. $m/z = 257.1$ (M+H).

4.2.10. 2-Hydroxy-*N*-(4-methoxybenzylidene)benzohydrazide TFA salt (A6)

General procedure A was used to form the imine bond using 4-methoxybenzaldehyde. An off-white solid was produced after purification. ^1H NMR (300 MHz, DMSO) δ 11.92 (s, 1H), 11.73 (s, 1H), 8.38 (s, 1H), 7.87 (d, $J = 7.2$ Hz, 1H), 7.68 (d, $J = 8.9$ Hz, 1H), 7.45–7.39 (m, 1H), 7.29–7.12 (m, 1H), 7.02 (d, $J = 8.7$ Hz, 2H), 6.94 (t, $J = 7.8$ Hz, 2H), 6.53 (s, 1H), 3.80 (s, 3H). LCMS: $t_R = 10.34$ min. $m/z = 271.2$ (M+H).

4.2.11. 2-Hydroxy-*N*-(4-nitrobenzylidene)benzohydrazide TFA salt (A7)

General procedure A was used to form the imine bond using 4-nitrobenzaldehyde and after purification, an off-white solid was produced. ^1H NMR (300 MHz, DMSO) δ 12.30 (s, 1H), 11.69 (s, 1H), 10.96 (s, 1H), 8.03–7.90 (m, 1H), 7.90–7.82 (m, 1H), 7.71–7.61 (m, 1H), 7.49–7.43 (m, 1H), 7.28–7.17 (m, 2H), 7.02–6.91 (m, 1H), 6.53 (s, 1H), 6.38 (d, $J = 9.7$ Hz, 1H). LCMS: $t_R = 10.68$ min. $m/z = 285.9$ (M+H).

4.2.12. 2-Hydroxy-*N*-phenethylbenzamide (A8)

General procedure B was used to couple salicylic acid to phenethylamine. The reaction was carried out at room temperature overnight and after HPLC purification, a white solid was produced. ^1H NMR (300 MHz, CDCl_3) δ 12.37 (s, 1H), 7.46–7.16 (m, 7H), 7.07–6.98 (m, 1H), 6.89–6.79 (m, 1H), 6.33 (s, 1H), 3.81–3.71 (m, 2H), 2.98 (t, $J = 6.8$ Hz, 2H). LCMS: $t_R = 12.12$ min. $m/z = 242.3$ (M+H).

4.2.13. 2-Hydroxy-*N*-(3-phenylpropyl)benzamide (A9)

General procedure B was used to couple salicylic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. A white solid was produced after purification. ^1H NMR (300 MHz, CDCl_3) δ 12.42 (s, 1H), 7.44–7.17 (m, 6H), 7.12 (d, $J = 7.9$ Hz, 1H), 7.00 (d, $J = 8.4$ Hz, 1H), 6.82 (t, $J = 7.6$ Hz, 1H), 6.29 (s, 1H), 3.53 (dd, $J = 13.1$, 6.4 Hz, 2H), 2.77 (t, $J = 7.4$ Hz, 2H), 2.02 (p, $J = 7.2$ Hz, 2H). LCMS: $t_R = 13.90$ min. $m/z = 256.3$ (M+H).

4.2.14. 2-Hydroxy-*N*-(4-phenylbutyl)benzamide (A10)

General procedure B was used to couple salicylic acid to 4-phenylbutylamine. The reaction was carried out at room temperature overnight. An off-white solid was produced following HPLC purification. ^1H NMR (300 MHz, CDCl_3) δ 7.39 (ddd, $J = 8.7$, 7.5, 1.5 Hz, 1H), 7.34–7.24 (m, 3H), 7.20 (t, $J = 6.7$ Hz, 3H), 6.98 (d, $J = 8.4$ Hz, 1H), 6.87–6.78 (m, 1H), 6.27 (s, 1H), 3.47 (dd, $J = 12.8$, 6.8 Hz, 2H), 2.68 (t, $J = 7.1$ Hz, 2H), 1.79–1.62 (m, 4H). LCMS: $t_R = 13.90$ min. $m/z = 270.4$ (M+H).

4.2.15. *N*-(3-Phenylpropyl)benzamide (A11)

General procedure B was used to couple benzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced an off-white solid after preparative HPLC. ^1H NMR (300 MHz, CDCl_3) δ 7.75–7.67 (m, 2H), 7.58–7.40 (m, 3H), 7.38–7.29 (m, 2H), 7.29–7.20 (m, 3H), 6.17 (s, 1H), 3.55 (dd, $J = 13.4$, 6.5 Hz, 2H), 2.77 (t, $J = 7.5$ Hz, 2H), 2.08–1.94 (m, 2H). LCMS: $t_R = 11.34$ min. $m/z = 240.3$ (M+H).

4.2.16. 3-Hydroxy-*N*-(3-phenylpropyl)benzamide (A12)

General procedure B was used to couple 3-hydroxybenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.45 (s, 1H), 7.35–7.26 (m, 2H), 7.22 (d, $J = 6.3$ Hz, 4H), 7.08–6.95 (m, 2H), 6.51 (s, 1H), 6.10 (s, 1H), 3.51

(dd, $J = 13.3$, 6.7 Hz, 2H), 2.73 (t, $J = 7.6$ Hz, 2H), 2.03–1.91 (m, 2H). LCMS: $t_R = 9.90$ min. $m/z = 256.2$ (M+H).

4.2.17. 4-Hydroxy-*N*-(3-phenylpropyl)benzamide (A13)

General procedure B was used to couple 4-hydroxybenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. A white solid was produced after purification. ^1H NMR (300 MHz, CDCl_3) δ 7.56–7.48 (m, 2H), 7.33–7.25 (m, 2H), 7.23–7.15 (m, 3H), 6.86–6.77 (m, 2H), 6.07 (s, 1H), 3.49 (dd, $J = 12.9$, 6.9 Hz, 2H), 2.72 (t, $J = 7.5$ Hz, 2H), 2.03–1.90 (m, 2H). LCMS: $t_R = 9.98$ min. $m/z = 256.3$ (M+H).

4.2.18. 2-Methyl-*N*-(3-phenylpropyl)benzamide (A14)

General procedure B was used to couple 2-methylbenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and subsequently purified using HPLC, producing an off-white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.36–7.10 (m, 9H), 5.79 (s, 1H), 3.47 (dd, $J = 13.6$, 6.6 Hz, 2H), 2.73 (t, $J = 7.6$ Hz, 2H), 2.43 (s, 3H), 2.00–1.89 (m, 2H). LCMS: $t_R = 11.68$ min. $m/z = 254.2$ (M+H).

4.2.19. 2-Methoxy-*N*-(3-phenylpropyl)benzamide (A15)

General procedure B was used to couple 2-methoxybenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 8.22 (dd, $J = 7.8$, 1.8 Hz, 1H), 7.90 (s, 1H), 7.48–7.40 (m, 1H), 7.34–7.24 (m, 2H), 7.25–7.15 (m, 3H), 7.13–7.06 (m, 1H), 6.98 (d, $J = 8.3$ Hz, 1H), 3.96 (s, 3H), 3.50 (dd, $J = 12.9$, 7.0 Hz, 2H), 2.74 (t, $J = 7.5$ Hz, 2H), 1.96 (dt, $J = 14.7$, 7.3 Hz, 2H). LCMS: $t_R = 11.90$ min. $m/z = 270.3$ (M+H).

4.2.20. 2-Nitro-*N*-(3-phenylpropyl)benzamide (A16)

General procedure B was used to couple 2-nitrobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight which produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 8.04 (dd, $J = 8.1$, 1.1 Hz, 1H), 7.60 (dtd, $J = 17.2$, 7.5, 1.4 Hz, 2H), 7.43 (dd, $J = 7.4$, 1.5 Hz, 1H), 7.35–7.24 (m, 2H), 7.26–7.14 (m, 3H), 5.83 (s, 1H), 3.49 (dd, $J = 13.1$, 6.9 Hz, 2H), 2.75 (t, $J = 7.4$ Hz, 2H), 2.04–1.91 (m, 2H). LCMS: $t_R = 11.01$ min. $m/z = 285.2$ (M+H).

4.2.21. 2-Fluoro-*N*-(3-phenylpropyl)benzamide (A17)

General procedure B was used to couple 2-fluorobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight which produced a white solid after purification. ^1H NMR (300 MHz, CDCl_3) δ 8.10 (td, $J = 7.9$, 1.9 Hz, 1H), 7.52–7.42 (m, 1H), 7.34–7.27 (m, 3H), 7.24–7.16 (m, 3H), 7.15–7.06 (m, 1H), 6.75 (s, 1H), 3.52 (q, $J = 5.8$ Hz, 2H), 2.74 (t, $J = 7.4$ Hz, 2H), 1.98 (dt, $J = 14.7$, 7.4 Hz, 2H). LCMS: $t_R = 12.34$ min. $m/z = 258.3$ (M+H).

4.2.22. 2-Chloro-*N*-(3-phenylpropyl)benzamide (A18)

General procedure B was used to couple 2-chlorobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. After HPLC purification, a white solid was produced. ^1H NMR (300 MHz, CDCl_3) δ 7.67–7.54 (m, 1H), 7.42–7.10 (m, 8H), 6.24 (s, 1H), 3.50 (q, $J = 10.0$ Hz, 2H), 2.75 (t, $J = 7.3$ Hz, 2H), 2.05–1.89 (m, 2H). LCMS: $t_R = 11.57$ min. $m/z = 274.1$ (M+H).

4.2.23. 2-Bromo-*N*-(3-phenylpropyl)benzamide (A19)

General procedure B was used to couple 2-bromobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.58 (d, $J = 7.0$ Hz, 1H), 7.49 (dd, $J = 7.6$, 1.8 Hz, 1H), 7.39–7.15 (m, 7H), 6.02 (s, 1H), 3.50 (dd, $J = 13.4$, 6.7 Hz, 2H), 2.76 (t, $J = 7.4$ Hz, 2H), 1.97 (dt, $J = 14.6$, 7.2 Hz, 2H). LCMS: $t_R = 12.01$ min. $m/z = 320.1$ (M+H).

4.2.24. 2-Iodo-N-(3-phenylpropyl)benzamide (A20)

General procedure B was used to couple 2-iodobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid after purification. ^1H NMR (300 MHz, CDCl_3) δ 7.90–7.80 (m, 1H), 7.40–7.15 (m, 7H), 7.13–7.03 (m, 1H), 5.77 (s, 1H), 3.50 (dd, J = 13.5, 6.6 Hz, 2H), 2.77 (t, J = 7.5 Hz, 2H), 1.99 (dt, J = 14.7, 7.2 Hz, 2H). LCMS: t_R = 12.34 min. m/z = 366.1 (M+H).

4.2.25. 2-Cyano-N-(3-phenylpropyl)benzamide (A21)

General procedure B was used to couple 2-cyanobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. A white solid was produced after purification. ^1H NMR (300 MHz, CDCl_3) δ 7.81–7.74 (m, 2H), 7.73–7.56 (m, 2H), 7.37–7.20 (m, 5H), 6.26 (s, 1H), 3.59 (dd, J = 12.9, 7.0 Hz, 2H), 2.80 (t, J = 7.6 Hz, 2H), 2.12–1.99 (m, 2H). LCMS: t_R = 11.90 min. m/z = 265.2 (M+H). HRMS m/z calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}$ (M+H), 265.1341; found, 265.1339.

4.2.26. 2-Amino-N-(3-phenylpropyl)benzamide (A22)

General procedure B was used to couple 2-aminobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced an off-white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.37–7.25 (m, 2H), 7.25–7.18 (m, 3H), 7.15 (dd, J = 10.0, 4.7 Hz, 2H), 6.79–6.54 (m, 2H), 6.04 (s, 1H), 5.00 (s, 2H), 3.45 (dd, J = 12.9, 6.2 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 2.04–1.86 (m, 2H). LCMS: t_R = 12.01 min. m/z = 255.3 (M+H).

4.2.27. 1-Hydroxy-N-(3-phenylpropyl)-2-naphthamide (A23)

General procedure B was used to couple 1-hydroxy-2-naphthoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. After purification, a white solid was produced. ^1H NMR (300 MHz, CDCl_3) δ 8.41 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 7.5 Hz, 1H), 7.61–7.47 (m, 2H), 7.37–7.27 (m, 2H), 7.27–7.18 (m, 4H), 7.04 (d, J = 8.8 Hz, 1H), 6.25 (s, 1H), 3.55 (dd, J = 12.8, 6.9 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.08–1.96 (m, 2H). LCMS: t_R = 17.02 min. m/z = 306.2 (M+H).

4.2.28. 3-Hydroxy-N-(3-phenylpropyl)-2-naphthamide (A24)

General procedure B was used to couple 3-hydroxy-2-naphthoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. HPLC purification produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 11.84 (s, 1H), 7.72 (t, J = 8.9 Hz, 2H), 7.60 (s, 1H), 7.54–7.46 (m, 1H), 7.42–7.34 (m, 2H), 7.34–7.27 (m, 5H), 6.41 (s, 1H), 3.62 (dd, J = 13.6, 5.7 Hz, 2H), 2.84 (t, J = 7.2 Hz, 2H), 2.10 (p, J = 7.1 Hz, 2H). LCMS: t_R = 15.57 min. m/z = 306.3 (M+H).

4.2.29. 2-Hydroxy-N-(3-phenylpropyl)-1-naphthamide (A25)

General procedure B was used to couple 2-hydroxy-1-naphthoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid after HPLC purification. ^1H NMR (300 MHz, CDCl_3) δ 11.49 (s, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.84–7.76 (m, 2H), 7.56–7.46 (m, 1H), 7.41–7.12 (m, 7H), 6.35 (s, 1H), 3.61 (dd, J = 13.7, 6.6 Hz, 2H), 2.78 (t, J = 7.5 Hz, 2H), 2.10–1.97 (m, 2H). LCMS: t_R = 13.12 min. m/z = 306.3 (M+H). HRMS m/z calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_2$ (M+H), 306.1494; found, 306.1495.

4.2.30. N-(3-Phenylpropyl)benzo[d][1,3]dioxole-5-carboxamide (A26)

General procedure B was used to couple piperonylic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.36–7.25 (m, 3H), 7.25–7.12 (m, 4H), 6.84–6.76 (m, 1H), 6.02 (s, 2H), 5.93 (s, 1H), 3.48 (dd, J = 12.9, 6.8 Hz, 2H), 2.73

(t, J = 7.5 Hz, 2H), 2.02–1.90 (m, 2H). LCMS: t_R = 12.12 min. m/z = 284.2 (M+H).

4.2.31. N-(3-Phenylpropyl)picolinamide (A27)

General procedure B was used to couple picolinic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. A clear oil was produced after purification. ^1H NMR (300 MHz, CDCl_3) δ 8.54 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.23–8.17 (m, 1H), 8.10 (s, 1H), 7.85 (td, J = 7.7, 1.7 Hz, 1H), 7.42 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.33–7.26 (m, 2H), 7.24–7.14 (m, 3H), 3.52 (dd, J = 13.3, 7.0 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 1.98 (dt, J = 9.1, 7.4 Hz, 2H). LCMS: t_R = 12.57 min. m/z = 241.4 (M+H).

4.2.32. N-(3-Phenylpropyl)quinoline-2-carboxamide (A28)

General procedure B was used to couple quinoline-2-carboxylic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a white solid after purification. ^1H NMR (300 MHz, CDCl_3) δ 8.32 (m, 3H), 8.10 (d, J = 8.6 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.77 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 7.62 (t, J = 6.9 Hz, 1H), 7.33–7.27 (m, 2H), 7.26–7.17 (m, 3H), 3.58 (dd, J = 13.6, 6.9 Hz, 2H), 2.79 (t, J = 7.5 Hz, 2H), 2.05 (dt, J = 14.7, 7.5 Hz, 2H). LCMS: t_R = 14.90 min. m/z = 291.3 (M+H).

4.2.33. N-(3-Phenylpropyl)isoquinoline-3-carboxamide (A29)

General procedure B was used to couple isoquinoline-3-carboxylic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. Following HPLC purification, a clear oil was produced. ^1H NMR (300 MHz, CDCl_3) δ 9.15 (s, 1H), 8.62 (s, 1H), 8.30 (s, 1H), 8.08–7.94 (m, 2H), 7.80–7.65 (m, 2H), 7.37–7.12 (m, 5H), 3.58 (dd, J = 13.6, 6.7 Hz, 2H), 2.78 (t, J = 7.5 Hz, 2H), 2.03 (dt, J = 14.5, 7.1 Hz, 2H). LCMS: t_R = 14.12 min. m/z = 291.3 (M+H). HRMS m/z calcd for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}$ (M+H), 291.1497; found, 291.1496.

4.2.34. N-(3-Phenylpropyl)isoquinoline-1-carboxamide (A30)

General procedure B was used to couple isoquinoline-1-carboxylic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a clear oil after preparative HPLC purification. ^1H NMR (300 MHz, CDCl_3) δ 9.62 (d, J = 7.6 Hz, 1H), 8.45 (d, J = 5.5 Hz, 1H), 8.26 (s, 1H), 7.87–7.76 (m, 2H), 7.76–7.64 (m, 2H), 7.34–7.14 (m, 5H), 3.56 (dd, J = 13.4, 6.9 Hz, 2H), 2.79 (t, J = 7.5 Hz, 2H), 2.03 (dt, J = 14.7, 7.4 Hz, 2H). LCMS: t_R = 14.35 min. m/z = 291.3 (M+H). HRMS m/z calcd for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}$ (M+H), 291.1497; found, 291.1496.

4.2.35. 4-Amino-2-hydroxy-N-(3-phenylpropyl)benzamide (A31)

General procedure B was used to couple 4-amino-2-hydroxybenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced an orange solid after purification. ^1H NMR (300 MHz, CDCl_3) δ 7.34–7.17 (m, 5H), 6.89 (d, J = 8.5 Hz, 1H), 6.17 (d, J = 2.0 Hz, 1H), 6.08 (d, J = 8.5 Hz, 1H), 5.93 (s, 1H), 3.45 (dd, J = 13.3, 6.4 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 2.03–1.88 (m, 2H). LCMS: t_R = 9.34 min. m/z = 271.3 (M+H). HRMS m/z calcd for $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_2$ (M+H), 271.1447; found, 271.1444.

4.2.36. 2-Amino-5-methoxy-N-(3-phenylpropyl)benzamide (A32)

General procedure B was used to couple 2-amino-5-methoxybenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight. An off-white solid was produced after purification. ^1H NMR (300 MHz, CDCl_3) δ 7.34–7.26 (m, 2H), 7.26–7.18 (m, 3H), 7.01–6.89 (m, 2H), 6.80 (d, J = 2.6 Hz, 1H), 6.26 (s, 1H), 3.78 (s, 3H), 3.46 (dd, J = 12.9, 6.7 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 2.03–1.90 (m, 2H). LCMS: t_R = 9.90 min. m/z = 285.3 (M+H).

4.2.37. 2-Amino-5-chloro-N-(3-phenylpropyl)benzamide (A33)

General procedure B was used to couple 2-amino-5-chlorobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced an off-white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.38–7.17 (m, 5H), 7.13 (ddd, J = 8.7, 2.3, 1.4 Hz, 1H), 7.04 (d, J = 2.4 Hz, 1H), 6.60 (dd, J = 8.7, 1.3 Hz, 1H), 5.91 (s, 1H), 4.79 (s, 2H), 3.45 (dd, J = 12.7, 6.9 Hz, 2H), 2.73 (t, J = 7.4 Hz, 2H), 2.02–1.90 (m, 2H). LCMS: t_R = 13.35 min. m/z = 289.3 (M+H).

4.2.38. 2-Amino-5-nitro-N-(3-phenylpropyl)benzamide (A34)

General procedure B was used to couple 2-amino-5-nitrobenzoic acid to 3-phenylpropylamine. The reaction was carried out at room temperature overnight and produced a yellow solid after purification. ^1H NMR (300 MHz, CDCl_3) δ 8.21–8.17 (m, 1H), 8.16–8.06 (m, 1H), 7.40–7.31 (m, 2H), 7.30–7.18 (m, 3H), 6.67 (dd, J = 9.1, 1.6 Hz, 1H), 6.54 (s, 2H), 6.14 (s, 1H), 3.52 (q, J = 7.3 Hz, 2H), 2.79 (t, J = 7.3 Hz, 2H), 2.04 (p, J = 6.7 Hz, 2H). LCMS: t_R = 12.79 min. m/z = 300.4 (M+H). HRMS m/z calcd for $\text{C}_{16}\text{H}_{18}\text{N}_3\text{O}_3$ (M+H), 300.1348; found, 300.1347.

4.2.39. N-Methyl-3-phenylpropan-1-amine

Two millimoles of 3-phenylpropylamine and 2.2 mmol of N-methylmorpholine was dissolved in THF at room temperature in a round bottom flask. To this, iodomethane was added to the flask in one portion. The reaction was mixed overnight at room temperature. The next day, the precipitate was filtered away and the THF was evaporated away under reduced pressure. The crude mixture was carried on without any work-up. LCMS: t_R = 9.12 min. m/z = 150.0 (M+H).

4.2.40. 2-Hydroxy-N-methyl-N-(3-phenylpropyl)benzamide (A35)

General procedure B was used to couple salicylic acid to N-methyl-3-phenylpropan-1-amine. The reaction was carried out at room temperature overnight and produced a white solid. 2:1 mixture of *cis/trans*. *Cis*: ^1H NMR (300 MHz, CDCl_3) δ 7.59–7.08 (m, 6H), 7.07–6.69 (m, 3H), 3.49 (m, 2H), 2.87 (s, 3H), 2.55 (t, J = 7.5 Hz, 2H), 1.91–1.69 (m, 2H). *Trans*: ^1H NMR (300 MHz, CDCl_3) δ 7.59–7.08 (m, 6H), 7.07–6.69 (m, 3H), 3.27–3.15 (m, 2H), 3.00 (s, 3H), 2.45 (t, J = 8.0 Hz, 2H), 1.91–1.69 (m, 2H). LCMS: t_R = 11.12 min. m/z = 270.3 (M+H). HRMS m/z calcd for $\text{C}_{17}\text{H}_{20}\text{NO}_2$ (M+H), 270.1494; found, 270.1494.

4.2.41. 2-(2-Hydroxyphenyl)-N-phenethylacetamide (A36)

General procedure B was used to couple 2-(2-hydroxyphenyl)acetic acid to 2-phenethylamine. The reaction was carried out at room temperature overnight. Following purification, an off-white solid was produced. ^1H NMR (300 MHz, CDCl_3) δ 7.33–7.16 (m, 4H), 7.14–7.09 (m, 2H), 6.97 (d, J = 7.9 Hz, 2H), 6.83 (t, J = 7.4 Hz, 1H), 5.94 (s, 1H), 3.61–3.40 (m, 4H), 2.80 (t, J = 6.9 Hz, 2H). LCMS: t_R = 11.23 min. m/z = 256.2 (M+H). HRMS m/z calcd for $\text{C}_{16}\text{H}_{18}\text{NO}_2$ (M+H), 256.1338; found, 256.1336.

4.2.42. N-Benzyl-3-(2-hydroxyphenyl)propanamide (A37)

General procedure B was used to couple 3-(2-hydroxyphenyl)propanoic acid to benzylamine. The reaction was carried out at room temperature overnight. HPLC purification produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 8.69 (s, 1H), 7.36–7.22 (m, 3H), 7.22–7.10 (m, 3H), 7.05 (dd, J = 7.5, 1.6 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 6.89–6.79 (m, 1H), 5.76 (s, 1H), 4.42 (d, J = 5.7 Hz, 2H), 3.00–2.92 (m, 2H), 2.69–2.61 (m, 2H). LCMS: t_R = 10.90 min. m/z = 256.3 (M+H).

4.2.43. 3-(2-Hydroxyphenyl)-N-phenylpropanamide (A38)

In a round bottom flask, 1 mmol of dihydrocoumarin was dissolved in DCM. To this, 1.1 mmol of aniline was added with

.25 mmol of DMAP. The reaction was mixed overnight at room temperature. Following this, the reaction was heated for 8 h at 70 °C. Upon completion of the reaction, the DCM was washed with saturated bicarbonate solution (1×) and with 2 M HCl (1×). The DCM was dried over Na_2SO_4 and the solvent was removed under reduced pressure. The crude reaction material was carried on to preparative HPLC without further work-up and produced a white solid. ^1H NMR (300 MHz, CDCl_3) δ 8.39 (s, 1H), 7.45 (d, J = 8.0 Hz, 2H), 7.37–7.26 (m, 3H), 7.16–7.07 (m, 3H), 6.95–6.81 (m, 2H), 3.03–2.96 (m, 2H), 2.85–2.77 (m, 2H). LCMS: t_R = 10.79 min. m/z = 242.4 (M+H).

4.2.44. N-(2-Hydroxyphenyl)-4-phenylbutanamide (A39)

General procedure B was used to couple 4-phenylbutanoic acid to 2-aminophenol. The reaction was carried out at room temperature overnight. This produced a white solid following HPLC purification. ^1H NMR (300 MHz, CDCl_3) δ 8.77 (s, 1H), 7.37–7.27 (m, 2H), 7.25–7.15 (m, 3H), 7.15–7.09 (m, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.95–6.80 (m, 2H), 2.74 (t, J = 7.4 Hz, 2H), 2.45 (t, J = 7.5 Hz, 2H), 2.17–2.04 (m, 2H). LCMS: t_R = 11.68 min. m/z = 256.2 (M+H).

4.2.45. 2-Hydroxy-N-(2-phenoxyethyl)benzamide (A40)

General procedure B was used to couple salicylic acid to 2-phenoxyethanamine. The reaction was carried out at room temperature overnight. Following HPLC purification, a white solid was produced. ^1H NMR (300 MHz, CDCl_3) δ 12.24 (s, 1H), 7.46–7.26 (m, 4H), 7.03–6.96 (m, 2H), 6.93 (d, J = 7.9 Hz, 2H), 6.85 (t, J = 7.6 Hz, 1H), 6.77 (s, 1H), 4.17 (d, J = 5.0 Hz, 2H), 3.88 (dd, J = 10.4, 5.3 Hz, 2H). LCMS: t_R = 13.12 min. m/z = 258.2 (M+H).

4.2.46. 2-Amino-N-(2-phenoxyethyl)benzamide (A41)

General procedure B was used to couple 2-aminobenzoic acid to 2-phenoxyethanamine. The reaction was carried out at room temperature overnight and produced a white solid following HPLC purification. ^1H NMR (300 MHz, CDCl_3) δ 7.39–7.14 (m, 4H), 7.02–6.87 (m, 3H), 6.71–6.62 (m, 2H), 6.57 (s, 1H), 5.26 (s, 2H), 4.14 (t, J = 5.1 Hz, 2H), 3.83 (dd, J = 10.6, 5.3 Hz, 2H). LCMS: t_R = 12.01 min. m/z = 257.2 (M+H).

Acknowledgement

This study was supported by Public Health Service grants R01AI071341 to D.A.E. and 5R43AI084244 to D.B.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bmc.2011.10.026.

References and notes

- Basu, D.; Walkiewicz, M. P.; Frieman, M.; Baric, R. S.; Auble, D. T.; Engel, D. A. *J. Virol.* **2009**, *83*, 1881.
- Simonsen, L.; Reichert, T. A.; Viboud, C.; Blackwelder, W. C.; Taylor, R. J.; Miller, M. A. *Arch. Intern. Med.* **2005**, *165*, 265.
- Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Bridges, C. B.; Cox, N. J.; Fukuda, K. *JAMA-J. Am. Med. Assoc.* **2004**, *292*, 1333.
- Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L. J.; Fukuda, K. *JAMA-J. Am. Med. Assoc.* **2003**, *289*, 179.
- Reid, A. H.; Taubenberger, J. K.; Fanning, T. G. *Microb. Infect.* **2001**, *3*, 81.
- Vittorio Farina, J. D. B. *Angew. Chem., Int. Ed.* **2006**, *45*, 7330.
- Chen, H.; Smith, G. J. D.; Li, K. S.; Wang, J.; Fan, X. H.; Rayner, J. M.; Vijaykrishna, D.; Zhang, J. X.; Zhang, L. J.; Guo, C. T.; Cheung, C. L.; Xu, K. M.; Duan, L.; Huang, K.; Qin, K.; Leung, Y. H. C.; Wu, W. L.; Lu, H. R.; Chen, Y.; Xia, N. S.; Naipospos, T. S. P.; Yuen, K. Y.; Hassan, S. S.; Bahri, S.; Nguyen, T. D.; Webster, R. G.; Peiris, J. S. M.; Guan, Y. P. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 2845.
- Ducatez, M. F.; Olinger, C. M.; Owoade, A. A.; De Landtsheer, S.; Ammerlaan, W.; Niesters, H. G. M.; Osterhaus, A. D. M. E.; Fouchier, R. A. M.; Muller, C. P. *Nature* **2006**, *442*, 37.

9. Olsen, B.; Munster, V. J.; Wallensten, A.; Waldenström, J.; Osterhaus, A. D. M. E.; Fouchier, R. A. M. *Science* **2006**, 312, 384.
10. Webster, R. G.; Govorkova, E. A. *New Engl. J. Med.* **2006**, 355, 2174.
11. Abdel-Ghaffar, A. N.; Chotpitayasundh, T.; Gao, Z.; Hayden, F. G.; Nguyen, D. H.; de Jong, M. D.; Naghdaliyev, A.; Peiris, J. S.; Shindo, N.; Soerooso, S.; Uyeki, T. M. *N. Engl. J. Med.* **2008**, 358, 261.
12. Hayman, A.; Comely, S.; Lackenby, A.; Hartgroves, L. C. S.; Goodbourn, S.; McCauley, J. W.; Barclay, W. S. *J. Virol.* **2007**, 81, 2318.
13. Lera, E.; T. Wörner, N.; Sancosmed, M.; Fàbregas, A.; Casquero, A.; Melendo, S.; Miserachs, M.; Tórtola, T.; Borrego, A.; Campins, M.; Moraga, F.; Figueras, C.; Cebrián, R. *Eur. J. Pediatr.* **2011**, 1.
14. Pada, D.; Tambyah, P. A. *Microb. Infect.* **2011**, 13, 470.
15. Thickett, D. R.; Griffiths, M.; Perkins, G. D.; McAuley, D. F. *Thorax* **2010**, 65, 855.
16. Nichol, Kristin L.; Treanor, John J. *J. Infect. Dis.* **2006**, 194, S111.
17. Kieny, M. P.; Costa, A.; Hombach, J.; Carrasco, P.; Pervikov, Y.; Salisbury, D.; Greco, M.; Gust, I.; LaForce, M.; Franco-Paredes, C.; Santos, J. I.; D'Hondt, E.; Rimmelzwaan, G.; Karon, R.; Fukuda, K. *Vaccine* **2006**, 24, 6367.
18. Krug, R. M.; Aramini, J. M. *Trends Pharmacol. Sci.* **2009**, 30, 269.
19. Walkiewicz, M. P.; Basu, D.; Jablonski, J. J.; Geysen, H. M.; Engel, D. A. *J. Gen. Virol.* **2011**, 92, 60.
20. Hale, B. G.; Barclay, W. S.; Randall, R. E.; Russell, R. J. *Virology* **2008**, 378, 1.
21. Krug, R. M.; Yuan, W.; Noah, D. L.; Latham, A. G. *Virology* **2003**, 309, 181.
22. Yin, C.; Khan, J. A.; Swapna, G. V. T.; Ertekin, A.; Krug, R. M.; Tong, L.; Montelione, G. T. *J. Biol. Chem.* **2007**, 282, 20584.
23. Hatada, E.; Fukuda, R. *J. Gen. Virol.* **1992**, 73, 3325.
24. Min, J.-Y.; Krug, R. M. *Natl. Acad. Sci.* **2006**, 103, 7100.
25. Silverman, R. H. *J. Virol.* **2007**, 81, 12720.
26. Kochs, G.; Garcia-Sastre, A.; Martinez-Sobrido, L. *J. Virol.* **2007**, 81, 7011.
27. Nemeroff, M. E.; Barabino, S. M. L.; Li, Y.; Keller, W.; Krug, R. M. *Mol. Cell* **1998**, 1, 991.
28. Chen, Z.; Li, Y.; Krug, R. M. *EMBO J.* **1999**, 18, 2273.
29. Noah, D. L.; Twu, K. Y.; Krug, R. M. *Virology* **2003**, 307, 386.
30. Gale, M.; Katze, M. G. *Pharmacol. Ther.* **1998**, 78, 29.
31. Min, J.-Y.; Li, S.; Sen, G. C.; Krug, R. M. *Virology* **2007**, 363, 236.
32. Gack, M. U.; Albrecht, R. A.; Urano, T.; Inn, K.-S.; Huang, I. C.; Carnero, E.; Farzan, M.; Inoue, S.; Jung, J. U.; Garcia-Sastre, A. *Cell Host Microbe* **2009**, 5, 439.
33. Guo, Z.; Chen, L.-M.; Zeng, H.; Gomez, J. A.; Plowden, J.; Fujita, T.; Katz, J. M.; Donis, R. O.; Sambhara, S. *Am. J. Respir. Cell Mol. Biol.* **2007**, 36, 263.
34. Ludwig, S.; Wolff, T. *Cell Host Microbe* **2009**, 5, 420.
35. Garcia-Sastre, A.; Egorov, A.; Matassov, D.; Brandt, S.; Levy, D. E.; Durbin, J. E.; Palese, P.; Muster, T. *Virology* **1998**, 252, 324.
36. Reed, L.; Muench, H. *Am. J. Hyg.* **1938**, 27, 943.